Anxiety disorders

Dr. Woodrow Myers Joins Freespira Board of Directors

Retrieved on: 
Tuesday, July 13, 2021
Psychiatry, Medical specialties, Clinical medicine, Anxiety disorders, Psychiatric diagnosis, Adverse childhood experiences, Post-traumatic stress disorder, Aftermath of war, Panic disorder, Psychological trauma, Myers

KIRKLAND, Wash., July 13, 2021 /PRNewswire/ -- Freespira, Inc. , maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, today announced that Woodrow (Woody) Myers, MD, has joined the company's Board of Directors.

Key Points: 
  • KIRKLAND, Wash., July 13, 2021 /PRNewswire/ -- Freespira, Inc. , maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, today announced that Woodrow (Woody) Myers, MD, has joined the company's Board of Directors.
  • Dr. Myers is a nationally recognized leader in the development of healthcare quality initiatives and advanced healthcare management programs.
  • "I'm excited to join Freespira's Board of Directors to help the company continue to expand its already strong reach.
  • Freespira CEODean Sawyer commented, "We're honored that Dr. Myers is joining our Board of Directors.

Helping young Canadians get their health back on track after more than a year of COVID-19 pandemic lockdown

Retrieved on: 
Thursday, July 8, 2021
Mind, Self, Psychology, Emotions, Psychiatric diagnosis, Anxiety disorders, Disability, Mental health, Social constructionism, Irritability, Obsessive–compulsive disorder, COVID-19 pandemic

Helping teens get their mental health and well-being back on track after more than a year of COVID-19 pandemic lockdown.

Key Points: 
  • Helping teens get their mental health and well-being back on track after more than a year of COVID-19 pandemic lockdown.
  • Quashis a free, made-in-Canada app based on behaviour change science to help teens quit their way, free of the judgement that can often lead to setbacks.
  • A recent study shows that during the pandemic, about 70 per cent of youth ages six to 18 experienced depression, anxiety, irritability, a lower attention span, or obsessions and compulsions.
  • The Lung Health Foundation is the leading national charity dedicated to improving the lung health of Canadians.

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

Retrieved on: 
Tuesday, July 6, 2021
Post-traumatic stress disorder, Psychiatry, Psychology, Mind, Adverse childhood experiences, Anxiety disorders, Aftermath of war, Nicotinic antagonists, Clinician Administered PTSD Scale, Psychological trauma, BNC-210, Child PTSD Symptom Scale

The ATTUNE Study is a randomised, double-blind, placebo-controlled, multi-centre Phase 2b clinical trial with a 12-week treatment period.

Key Points: 
  • The ATTUNE Study is a randomised, double-blind, placebo-controlled, multi-centre Phase 2b clinical trial with a 12-week treatment period.
  • The primary objective is to compare BNC210 to placebo on the improvement in PTSD symptom severity as measured by the Clinician Administered PTSD scale for DSM-5 (CAPS-5) following 12 weeks of treatment.
  • An oral tablet formulationof BNC210, showing much improved absorption over the previous liquid suspension formulation, will be evaluated in this study.
  • BNC210 oral tablet formulation is currently being evaluated in a second Phase 2b trial for the treatment of Post-Traumatic Stress Disorder (PTSD) for which it was granted Fast Track designation by the FDA.

Inner Vice - New study looks at the role of personality and emotions in the development of compulsive habits

Retrieved on: 
Tuesday, June 29, 2021
Mind, Self, Psychology, Psychiatric diagnosis, Anxiety disorders, Behaviorism, HABIT, Learning, Compulsive behavior, g factor, Emotional Intelligence

Analyzing data collected from 12,259 people who took the Emotional Intelligence Test , PsychTests' researchers compared people who engage in compulsive habits ("Habit-Engagers") to those who don't ("Habit-Resisters").

Key Points: 
  • Analyzing data collected from 12,259 people who took the Emotional Intelligence Test , PsychTests' researchers compared people who engage in compulsive habits ("Habit-Engagers") to those who don't ("Habit-Resisters").
  • PsychTests study also revealed that:
    59% of Habit-Engagers are very sensitive to criticism (compared to 20% of Habit-Resisters, a difference of 39%).
  • Compulsive habits are compulsive for a reason - because you keep doing the same thing and expecting a different result."
  • staff is comprised of a dedicated team of psychologists, test developers, researchers, statisticians, writers, and artificial intelligence experts (see ARCHProfile.com ).

'Since Your Life Story Would Make the Most Amazing Headline, What Would it Say?' - Two Special Brothers, a Reformed Ex-L.A. Gang Member and a Paralympic Purple-Heart Recipient, Continue to Remind Everyone That 'We Are All One Story'

Retrieved on: 
Monday, June 21, 2021
Medical specialties, Clinical medicine, Articles, Adverse childhood experiences, Mental health, Anxiety disorders, Anxiety, Emotions, Psychological trauma, Rattle, Major trauma

WAAOS is currently amassing an expanding library of uniquely heartfelt tales told by people from all walks of life.

Key Points: 
  • WAAOS is currently amassing an expanding library of uniquely heartfelt tales told by people from all walks of life.
  • "Well, for example, when you see my brother, when you see his scars from war, you physically know that he's been through some trauma.
  • Anxiety or depression or lost hopes and dreams: all that other life-stuff that rattles around in all our heads.
  • Having found that wisdom again, the brothers set out on a mission to help others remember the same truth: Each story is worth telling.

73% of US workers have some anxiety about returning to in-person work, new InnovateMR study finds

Retrieved on: 
Thursday, June 17, 2021
Anxiety disorders, Psychiatry, Psychology, Anxiety, Emotions, Mind, Psychiatric diagnosis, Educational psychology

Other findings of this study include:

Key Points: 
  • Other findings of this study include:
    31% of women reported being entirely anxious about returning to in-person work, compared to 16% of men.
  • 34% of men noted they were entirely relieved about the return to the office, compared to 24% of women.
  • 14% stated that concerns about their current physical appearance was a main source of anxiety for heading back to the office.
  • Political affiliation had little impact on anxiety levels: an almost equal number of Democrats and Republicans were entirely anxious to return at 21%.

Jim Harvey Joins Ascellus as Senior Vice President of National and Strategic Accounts

Retrieved on: 
Wednesday, June 16, 2021
Software, Internet, Professional services, Mental health, Technology, Infectious diseases, Small business, Insurance, Audio, Video, Human resources, Health, Physical therapy, Psychiatry, Articles, Adverse childhood experiences, Health, Post-traumatic stress disorder, Abnormal psychology, Mental health, Anxiety disorders, Psychological trauma

Ascellus (formerly IMCS Group), the leading behavioral health provider focused on helping injured workers restore their physical and emotional wellbeing, has announced Jim Harvey has joined the company as its new Senior Vice President of National Account Management and Strategy.

Key Points: 
  • Ascellus (formerly IMCS Group), the leading behavioral health provider focused on helping injured workers restore their physical and emotional wellbeing, has announced Jim Harvey has joined the company as its new Senior Vice President of National Account Management and Strategy.
  • Harvey has more than 20 years' leadership experience in the health technologies field, fostering outcomes fulfillment across multi-disciplinary teams.
  • "We're excited to team with Jim on introducing our solution-oriented Ascellus Connect platform to our industry partners."
  • The Ascellus platform provides treatment plans for pain management, workplace trauma, post-traumatic stress disorder (PTSD), COVID-19, and California Stress Claims.

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, Health, Clinical trials, Medical Supplies, Psychiatry, Anxiety disorders, Psychology, Mind, Psychiatric diagnosis, Abnormal psychology, Social anxiety disorder, Social anxiety, Generalized anxiety disorder, Anxiety

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the initial target indications for its proprietary psychedelic molecule CYB004.

Key Points: 
  • Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the initial target indications for its proprietary psychedelic molecule CYB004.
  • With the advent of the COVID-19 pandemic, rates of anxiety have increased 3-fold, leaving many folks in a debilitating state.
  • Various studies reviewing the improvements in anxiety with psychedelic treatments showed a significant response to therapy and were relatively well-tolerated.
  • "The decision to pursue anxiety disorders indications for CYB004 follows months of thoughtful, in-depth work by the Cybin development team.

Freespira Wins Juniper Research Future Digital Health Innovation Award for Best Mental Health Therapeutic Solution

Retrieved on: 
Tuesday, June 15, 2021
Psychiatry, Mind, Psychology, Psychiatric diagnosis, Anxiety disorders, Adverse childhood experiences, Post-traumatic stress disorder, Abnormal psychology, Panic disorder, Mental health, Psychological trauma

KIRKLAND, Wash., June 15, 2021 /PRNewswire/ -- Freespira, Inc. , the maker of the first FDA-cleared digital therapeutic proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder (PD) and post-traumatic stress disorder (PTSD), in just 28-days, today announced that the company has received Juniper Research's Future Digital Health Innovation Award for Best Mental Health Therapeutic Solution at the Platinum level.

Key Points: 
  • KIRKLAND, Wash., June 15, 2021 /PRNewswire/ -- Freespira, Inc. , the maker of the first FDA-cleared digital therapeutic proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder (PD) and post-traumatic stress disorder (PTSD), in just 28-days, today announced that the company has received Juniper Research's Future Digital Health Innovation Award for Best Mental Health Therapeutic Solution at the Platinum level.
  • The disruption to their lives is devastating, affecting everything from sleep, to their ability to work and maintain healthy personal relationships.
  • As the only digital solution built for at-home self-management, Freespira is user-friendly and efficient with twice-daily 17-minute treatments accompanied by remote coaching sessions.
  • Current organizations offering Freespira include Highmark Blue Cross Blue Shield, Children's Community Health Plan in Wisconsin, and Comcast NBC Universal.

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Retrieved on: 
Tuesday, June 8, 2021
Alternative medicine, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Psychiatry, Health, Adverse childhood experiences, Clinical psychology, Psychiatric diagnosis, Anxiety disorders, Post-traumatic stress disorder, Psychotherapy, Psychedelic therapy, Psychological trauma, Health professional

The study will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals.

Key Points: 
  • The study will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals.
  • To support the initiative, Cybins Chief Clinical Officer, Alex Belser, PhD and Bill Brennan, PhD (candidate) developed EMBARK.
  • The development of EMBARK has been guided by leading process evidence for the clinical efficacy of psychedelic-assisted psychotherapy and demonstrated theories of therapeutic action to support healing.
  • EMBARK was designed as a transdiagnostic psychotherapy model that can be adapted to address a range of clinical indications and populations.